PathoQuest Appoints Eric Cazergue as Chief Financial Officer
PARIS, FRANCE — April 06, 2021 – PathoQuest, a pioneer of Next Generation Sequencing (NGS)-based testing solutions for the quality control of biologics, today announced the appointment of Eric Cazergue as Chief Financial Officer. Mr. Cazergue’s international career in finance roles within the healthcare industry will be a key asset supporting PathoQuest’s scale-up and global expansion efforts.
As PathoQuest’s Chief Financial Officer and a member of PathoQuest’s leadership team, Mr. Cazergue will report directly to Jean-François Brepson, CEO of PathoQuest. In this role, he will have responsibility for the entirety of the company’s finance activities on a global basis, including coordinating those associated with the company’s U.S. subsidiary. Mr. Cazergue will have a critical role in supporting the scale-up of the company which is now accelerating its international expansion and industrialization to meet the growing needs of the biologics industry for NGS-based testing solutions.
“I am joining PathoQuest at an exciting time for the company as it is in the process of rapidly expanding its activities and setting up a lab in the U.S. I have dedicated 25 years of my career to the healthcare industry and am thrilled to contribute to the growth of PathoQuest’s NGS-based solutions for the biosafety of biologics,” stated Eric Cazergue, PathoQuest’s Chief Financial Officer. “PathoQuest presents significant strong growth opportunity that I will support by leveraging my previous successful experiences with mid-cap and large companies.”
“We are very happy to welcome Eric to PathoQuest. He has an impressive track record as CFO in the pharmaceutical industry at the international level,” commented PathoQuest’s CEO Jean-Francois Brepson. “Eric will be a key asset to help us to structure the company’s processes and coordinate key financial operations as we rapidly expand.”
Prior to joining PathoQuest, Mr. Cazergue was Finance & Operations Director at Corin France with responsibilities for coordinating the support functions in a post-acquisition and business recovery environment. In this role, he supported the evolution of the company’s new business model with the implementation of service models around technology solutions. Before this, he was Vice-President of Finance for EMEA APAC at Resmed, a medical device company, where he improved profitability in a price pressure context. He also supported business development and growth and made key contributions to local acquisitions and integration programs. Previous to the above, Mr. Cazergue was Chief Financial Officer at Sanofi Aventis Turkey where he supported the company’s strong business growth and organizational development while also contributing to improving profitability after the 2001 local major economic crisis which resulted in significant changes to the pharmaceuticals pricing model. He also was a key contributor in the local merger process of Rhone Poulenc/HMR and subsequently between Sanofi/Aventis. Mr. Cazergue holds a Master of Business Administration (MBA) from Emlyon Business School (EM Lyon) in Lyon, France, and a Master’s in Finance and Accounting (D.E.S.C.F) from the University of Lyon.
PathoQuest offers biopharmaceutical companies a game-changing genomic testing to ensuring the biosafety of biologics like cell and gene therapy products, vaccines, and recombinant drugs. It also enables a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines an NGS platform with proprietary sample preparation processes followed by an automated analysis pipeline using the company’s proprietary pathogen genome sequences databases.
PathoQuest entered into a strategic partnership with Charles River Laboratory (Boston, USA) in 2018.
Based on its technological platform, PathoQuest has also developed a metagenomic blood-based test (iDTECT®) designed to improve the diagnosis of infectious diseases and fight against antimicrobial resistance (AMR).
Marketing Manager at PathoQuest